The UK’s competition watchdog has imposed fines totalling more than £260m on pharmaceutical companies after an investigation found that they overcharged the NHS for hydrocortisone tablets for almost a decade.
The Competition and Markets Authority (CMA) found that the drug’s makers Auden Mckenzie and Actavis UK, now known as Accord-UK, used their position as the sole providers of hydrocortisone to inflate the price of the drug. Tens of thousands of people in the UK depend on hydrocortisone tablets to treat adrenal insufficiency, which includes life-threatening conditions such as Addison’s disease, the CMA said.
The investigation found that the companies were able to inflate the price of hydrocortisone tablets by more than 10,000% compared with the original branded version on sale in 2008. This meant the amount the NHS had to pay for a single pack of 10mg tablets rose from 70p in April 2008 to £88 by March 2016.
- The Fed Tries and Fails to Hide This Brutal Reality
- PayPal goes full 1984 in November…
- India Banks SHUTDOWN For 20 Days
- There are so many market indicators that we are heading towards a major financial crisis
- Federal Reserve and Government in the Sunshine Meeting Notice Alert! Advanced Notice of a Meeting under Expedited Procedures for a Closed Board Meeting on October 3, 2022
- It’s Impossible to State How Bad Things Actually Are
- It’s Going to Take Some Very Cool Heads to Keep the Blinken Administration from Destroying the World
- Banks are over leveraged by 2 quadrillion… The calm before the storm
- Putin is “The New Hitler” as Nuclear War With Russia Becoming Increasingly Probable
- Cool explanation on how Germany f***** itself.